Artificial Intelligence Oncology Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The global AI in oncology market is valued at approximately $3.05 billion in 2025, with figures from industry tracking sources placing it in the $3.1 billion range. The market is forecasted to reach roughly $11.52 billion by 2030, driven by sustained demand for improved cancer detection accuracy and personalized treatment protocols. AI technologies are being integrated across the oncology care continuum, from early diagnosis through radiotherapy planning and clinical trial matching.

• •Market valued at approximately USD 3.05-3.1 billion in 2025
• •Projected to reach USD 11.52 billion by 2030 at a 29.36% CAGR
• •Applications span medical imaging, genomics, clinical decision support, and drug discovery

The escalating global burden of cancer, with millions of new cases diagnosed annually, is a primary catalyst for AI adoption in oncology, as healthcare systems seek more scalable and accurate diagnostic capabilities. Rapid advancements in deep learning, computer vision, and natural language processing have significantly improved the precision of tumor detection and treatment recommendation systems. Regulatory support, including FDA breakthrough device designations for AI oncology tools, is accelerating clinical validation and commercial deployment.

• •Rising global cancer incidence driving demand for scalable diagnostic and therapeutic solutions
• •Breakthroughs in deep learning and computer vision improving tumor detection accuracy
• •Regulatory pathways and FDA designations accelerating AI tool commercialization

The market is segmented by cancer type, with breast cancer, lung cancer, prostate cancer, and colorectal cancer representing major focus areas for AI application. By component, the market comprises software solutions, hardware, and professional services. North America holds the largest market share due to advanced healthcare infrastructure, substantial R&D investment, and early adoption of AI technologies, while Europe and the Asia-Pacific region are experiencing rapid growth driven by expanding healthcare digitization initiatives.

• •Breast, lung, prostate, and colorectal cancers are leading application segments
• •Components include software solutions, hardware infrastructure, and professional services
• •North America leads, with Europe and Asia-Pacific as fastest-growing regional markets

What are the recent trends and outlook?

A prominent trend is the development of explainable AI and interpretable deep learning models to build clinician trust and satisfy regulatory transparency requirements. Multi-modal AI systems integrating medical imaging, genomic data, electronic health records, and pathology reports are becoming standard in precision oncology workflows. Generative AI and large language models are emerging in clinical documentation and drug discovery acceleration, with increasing numbers of AI oncology tools achieving regulatory approval and moving from pilot programs to routine clinical use.

• •Explainable AI gaining priority to meet regulatory transparency and clinician trust requirements
• •Multi-modal AI combining imaging, genomics, and EHR data for precision oncology
• •Increasing FDA approvals and transitions from pilot programs to standard clinical deployment